FDA approves new breast cancer treatment.
Thompson
Cheryl A
CA
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy*; D000069287:Capecitabine; D000075202:Contraindications; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D017277:Drug Approval; D004348:Drug Labeling; D034261:Epothilones / Q000008:administration & dosage* / Q000627:therapeutic use; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D050257:Tubulin Modulators / Q000008:administration & dosage* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D034261:Epothilones; D050257:Tubulin Modulators; D003841:Deoxycytidine; D000069287:Capecitabine; C430592:ixabepilone; D005472:Fluorouracil